User login
Key clinical point: The coadministration of histamine H2 receptor antagonists (H2RA) is unlikely to affect the efficacy of capecitabine monotherapy and capecitabine and oxaliplatin (CapeOX) regimen in patients with early-stage colorectal cancer (CRC).
Major finding: At 5 years, the relapse-free survival (RFS) in the H2RA and non-H2RA groups were 76.7% (95% CI 57.2%-88.1%) and 79.8% (95% CI 76.0%-83.0%), respectively, with RFS not being significantly different between the H2RA and non-H2RA groups of patients receiving capecitabine monotherapy or CapeOX (P = .772).
Study details: Findings are from a retrospective analysis of 552 patients with stage II-III CRC who received either capecitabine alone or CapeOX as adjuvant therapy. H2RA were coadministered to 30 patients.
Disclosures: This study was partly supported by the Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research and the Policy-based Medical Services Foundation in Japan. R Uozumi and H Kawazoe declared ties with various sources.
Source: Yamazaki T et al. Association between the co-administration of histamine H2 receptor antagonists and the effectiveness of capecitabine in patients with colorectal cancer: Propensity score analysis. J Cancer. 2022;13(10):3073-3083 (Aug 8). Doi: 10.7150/jca.73385
Key clinical point: The coadministration of histamine H2 receptor antagonists (H2RA) is unlikely to affect the efficacy of capecitabine monotherapy and capecitabine and oxaliplatin (CapeOX) regimen in patients with early-stage colorectal cancer (CRC).
Major finding: At 5 years, the relapse-free survival (RFS) in the H2RA and non-H2RA groups were 76.7% (95% CI 57.2%-88.1%) and 79.8% (95% CI 76.0%-83.0%), respectively, with RFS not being significantly different between the H2RA and non-H2RA groups of patients receiving capecitabine monotherapy or CapeOX (P = .772).
Study details: Findings are from a retrospective analysis of 552 patients with stage II-III CRC who received either capecitabine alone or CapeOX as adjuvant therapy. H2RA were coadministered to 30 patients.
Disclosures: This study was partly supported by the Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research and the Policy-based Medical Services Foundation in Japan. R Uozumi and H Kawazoe declared ties with various sources.
Source: Yamazaki T et al. Association between the co-administration of histamine H2 receptor antagonists and the effectiveness of capecitabine in patients with colorectal cancer: Propensity score analysis. J Cancer. 2022;13(10):3073-3083 (Aug 8). Doi: 10.7150/jca.73385
Key clinical point: The coadministration of histamine H2 receptor antagonists (H2RA) is unlikely to affect the efficacy of capecitabine monotherapy and capecitabine and oxaliplatin (CapeOX) regimen in patients with early-stage colorectal cancer (CRC).
Major finding: At 5 years, the relapse-free survival (RFS) in the H2RA and non-H2RA groups were 76.7% (95% CI 57.2%-88.1%) and 79.8% (95% CI 76.0%-83.0%), respectively, with RFS not being significantly different between the H2RA and non-H2RA groups of patients receiving capecitabine monotherapy or CapeOX (P = .772).
Study details: Findings are from a retrospective analysis of 552 patients with stage II-III CRC who received either capecitabine alone or CapeOX as adjuvant therapy. H2RA were coadministered to 30 patients.
Disclosures: This study was partly supported by the Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research and the Policy-based Medical Services Foundation in Japan. R Uozumi and H Kawazoe declared ties with various sources.
Source: Yamazaki T et al. Association between the co-administration of histamine H2 receptor antagonists and the effectiveness of capecitabine in patients with colorectal cancer: Propensity score analysis. J Cancer. 2022;13(10):3073-3083 (Aug 8). Doi: 10.7150/jca.73385